healthcare-thumbnail.png

Acute Myeloid Leukemia Therapeutics Market Research Report

Published: 2025 - January

Report Code: VMR-7722

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Acute Myeloid Leukemia Market Analysis 

The Acute Myeloid Leukemia (AML) market focuses on the diagnosis, treatment, and management of AML, a hematologic cancer affecting the blood and bone marrow. AML is characterized by the rapid growth of abnormal white blood cells that crowd out healthy cells, leading to severe complications. The market is driven by advancements in targeted therapies, immunotherapies, and stem cell transplants, which are shaping the treatment landscape.

Disruptive Impact and Opportunities:

The AML market is undergoing significant disruption due to the rapid development of novel therapies targeting specific molecular pathways, enhancing the precision of treatment. Emerging therapies, such as CAR-T cells and targeted inhibitors, offer substantial potential for higher efficacy and fewer side effects compared to traditional chemotherapy. This brings new opportunities for personalized treatment options and more favorable patient outcomes.

Acute Myeloid Leukemia Market Segmentation - Emerging Drugs

  • Omidubicel

  • Uproleselan

  • ALT 803

  • BPX-501

  • JNJ-75276617

  • AB001

Acute Myeloid Leukemia Market Segmentation - Marketed Drugs

  • Gilteritinib fumarate

  • Enasidenib mesylate

  • Ivosidenib

  • Gemtuzumab ozogamicin

Key Companies:

  • Pfizer Inc.

  • Novartis AG

  • Sanofi

  • Bristol Myers Squibb

  • Agios Pharmaceuticals

  • Abbvie

  • Astellas Pharma

Acute Myeloid Leukemia Market Segmentation - By Type

·  Chemotherapy-based treatments

  • Cytarabine-based regimens

  • Anthracycline-based regimens

  • Other chemotherapy drugs

·  Targeted therapies

  • FLT3 inhibitors

  • IDH inhibitors

  • BCL-2 inhibitors

  • Other targeted therapies

·  Immunotherapy

  • Monoclonal antibodies

  • CAR-T cell therapies

  • Bispecific T-cell engagers

·  Stem cell and bone marrow transplants

  • Allogeneic stem cell transplant

  • Autologous stem cell transplant

·  Other treatments

  • Epigenetic modifiers

  • Other investigational therapies

Acute Myeloid Leukemia Market Segmentation -  By Administration Type

  • Oral administration

    • Oral chemotherapy agents

    • Oral targeted therapies

    • Oral immunotherapies

  • Parenteral administration

    • Intravenous chemotherapy agents

    • Intravenous immunotherapies

    • Intravenous targeted therapies

    • Stem cell transplant-related administration

  • Subcutaneous administration

    • Subcutaneous monoclonal antibodies

    • Subcutaneous bispecific antibodies

What’s in It for You?

  • Insight into key drug developments and their market impact.

  • Detailed analysis of growth opportunities in the targeted therapies and immunotherapy segments.

  • Comprehensive understanding of competitive landscape and key players.

  • Identification of emerging drug trends and strategic moves by leading companies.

  • Support in making data-driven decisions for market entry and investment strategies.

Acute Myeloid Leukemia Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1 Acute Myeloid Leukemia Market - Executive Summary                                

               1.1 Introduction                              

               1.2 Objectives                  

               1.3 Key Findings               

                              1.3.1 Market Size 2025 & 2030: By Key Country (10MM) 

                              1.3.2 Global Market Size 2025 & 2030: By Key Segment   

                              1.3.3 Key Investments & Startup Analysis              

               1.4 Research Methodology                                                                       

2 Understanding the Disease                                    

               2.1 Disease Overview                    

               2.2 Classification                             

               2.3 Signs and Symptoms                              

               2.4 Risk Factors                

               2.5 Causes                        

               2.6 Disease Biology & Digital Innovations                              

               2.7 Stages & Staging System                      

               2.8 Diagnostic Algorithm                             

               2.9 Current Treatment Practices & Algorithm                      

               2.10 Current Standard of Care and Treatment Gaps                         

               2.11 Patient Demographics and Treatment Pathways                                                                    

3 Guidelines                                                                                  

4 Unmet Needs                                                                           

5 Epidemiology and Patient Population                                 

               5.1 Epidemiology Key Findings                   

               5.2 Assumptions and Rationale: 10MM                 

               5.3 Epidemiology Scenario: 10MM                          

               5.4 U.S. Epidemiology Scenario                 

               5.5 EU-5 Epidemiology                  

                              5.5.1 U.K. Epidemiology Scenario             

                              5.5.2 Germany Epidemiology Scenario    

                              5.5.3 France Epidemiology Scenario         

                              5.5.4 Italy Epidemiology Scenario             

                              5.5.5 Spain Epidemiology Scenario           

               5.6 Japan Epidemiology Scenario                             

               5.7 China Epidemiology Scenario                             

               5.8 Australia Epidemiology Scenario                       

               5.9 India Epidemiology Scenario                                                            

6 Real-world Data & Real-world Evidence                                                                                         

7 Drug Development Landscape                               

               7.1 Existing Key Drug Candidate Profiles/ Marketed Therapies                     

                              7.1.1 Gilteritinib Fumarate           

                                             7.1.1.1 Product Description

                                             7.1.1.2 Regulatory Milestones

                                             7.1.1.3 Other Developmental Activities

                                             7.1.1.4 Pivotal Clinical Trials

                                             7.1.1.5 Ongoing Current Pipeline Activity

                              7.1.2 Enasidenib Mesylate           

                                             7.1.2.1 Product Description

                                             7.1.2.2 Regulatory Milestones

                                             7.1.2.3 Other Developmental Activities

                                             7.1.2.4 Pivotal Clinical Trials

                                             7.1.2.5 Ongoing Current Pipeline Activity

                              7.1.3 Ivosidenib

                                             7.1.3.1 Product Description

                                             7.1.3.2 Regulatory Milestones

                                             7.1.3.3 Other Developmental Activities

                                             7.1.3.4 Pivotal Clinical Trials

                                             7.1.3.5 Ongoing Current Pipeline Activity

                              7.1.4 Gemtuzumab Ozogamicin 

                                             7.1.4.1 Product Description

                                             7.1.4.2 Regulatory Milestones

                                             7.1.4.3 Other Developmental Activities

                                             7.1.4.4 Pivotal Clinical Trials

                                             7.1.4.5 Ongoing Current Pipeline Activity

               7.2 Competitive Analysis and Differentiation                        

               7.3 Overview of Similar/Competing Drugs in Clinical Trials                            

               7.4 Future Trends and Emerging Drugs                   

                              7.4.1 ALT 803    

                                             7.4.1.1 Product Description

                                             7.4.1.2 Clinical Development

                                             7.4.1.3 Safety and Efficacy

                              7.4.2 BPX-501   

                                             7.4.2.1 Product Description

                                             7.4.2.2 Clinical Development

                                             7.4.2.3 Safety and Efficacy

                              7.4.3 JNJ-75276617        

                                             7.4.3.1 Product Description

                                             7.4.3.2 Clinical Development

                                             7.4.3.3 Safety and Efficacy

                              7.4.4 AB001       

                                             7.4.4.1 Product Description

                                             7.4.4.2 Clinical Development

                                             7.4.4.3 Safety and Efficacy                                            

8 Regulatory Strategy and Potential Challenges                                 

               8.1 Regulatory Pathways in Key Markets               

               8.2 Anticipated Regulatory Hurdles and Mitigation Strategies                      

               8.3 Case Studies in Oncology Drug Regulation                     

               8.4 Impact of Potential Changes to Regulatory Framework                                                                         

9 Commercial Landscape                                            

               9.1 Market Size & Growth Rates               

               9.2 Key Approvals & Anticipated Loss of Exclusivity                          

               9.3 PESTLE & Porter’s Five Forces Analysis                           

               9.4 Market Shares, Positioning/Ranking                 

               9.5 Market Drivers                         

               9.6 Identification of Threats                       

               9.7 Digital Evolution in Commercialization                                                                         

10 Market Segmentation                                            

               10.1 Market by Type                     

                              10.1.1 Myeloblastic leukemia     

                              10.1.2 Myelomonocytic leukemia             

                              10.1.3 Promyelocytic leukemia   

                              10.1.4 Monocytic leukemia         

                              10.1.5 Other leukemia types       

               10.2 Market by Therapy Type                    

                              10.2.1 Chemotherapy     

                              10.2.2 Targeted therapy

                              10.2.3 Immunotherapy  

                              10.2.4 Others                                                 

11 Pricing, Reimbursement, and Access                               

               11.1 Competitive Pricing Analysis                            

               11.2 Reimbursement Landscape and Challenges                

               11.3 Strategies for Market Access and Equity                      

               11.4 Patient Spending/Expenditure Analysis                                                                    

12 Future Trends, Disruptions, and Opportunities                                            

               12.1 Analysis of Emerging Trends                             

               12.2 Technological Impact                          

               12.3 Impact of Potential Market Disruptors                         

               12.4 Opportunities for Future Development and Expansion                          

               12.5 Considerations for Investment Opportunities                                                                       

13 Global Market Dynamics                                      

               13.1 Regional Regulatory Disparities                       

               13.2 Cross-Border Partnership Strategies                             

               13.3 Global Supply Chain Dynamics                        

               13.4 Case Studies: Success and Failure in Global Markets               

               13.5 Strategies for Global Expansion and Localization                                                                   

14 Company Profiles                                    

               14.1 Pfizer Inc.                 

               14.2 Novartis AG                            

               14.3 Sanofi                        

               14.4 Bristol Myers Squibb                           

               14.5 Agios Pharmaceuticals                        

               14.6 Abbvie                       

               14.7 Astellas Pharma                     

               14.8 Daiichi Sankyo Company, Limited                   

               14.9 Otsuka Pharmaceutical Co., Ltd.                     

               14.10 Partner Therapeutics, Inc.               

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.